Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | TYMP | P19971 | 1/20 | 0.33 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL269470 | 0.79 | HCAR2 (0.32) | HCAR2PDE3BPDE3ATYMPCYP1A2 | |
| SCHEMBL25131987 | 0.78 | PDE3B (0.35) | PDE3BPDE3A | |
| SCHEMBL10238804 | 0.76 | PDE3B (0.42) | HCAR2PDE3BPDE3ATYMPGDA | |
| SCHEMBL7674378 | 0.76 | LMNA (0.44) | TYMPKDM4ECA12PARP1CA9 | |
| SCHEMBL9016367 | 0.74 | TYMP (0.31) | TYMP | |
| SCHEMBL10127313 | 0.74 | NPC1 (0.44) | HCAR2PDE3BPDE3AKDM4ENPC1 | |
| SCHEMBL1484455 | 0.74 | TYMP (0.45) | TYMPNPC1RAB9A | |
| SCHEMBL20886374 | 0.71 | KDM4E (0.37) | HCAR2PDE3BPDE3ATYMPKDM4E | |
| SCHEMBL14309702 | 0.70 | DAO (0.38) | — | |
| SCHEMBL13360253 | 0.70 | LMNA (0.35) | TYMPKDM4ENPC1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10954251-B2 | Thienopyrimidine inhibitors of atypical protein kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-03-23 | — | — | US | disclosed |
| US-20190106433-A1 | THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | WINDTREE THERAPEUTICS, INC. | 2019-04-11 | — | — | US | disclosed |
| US-10183950-B2 | Thienopyrimidine inhibitors of atypical protein kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-01-22 | — | — | US | disclosed |
| US-20170166558-A1 | O-GLCNAC TRANSFERASE (OGT) INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-06-15 | — | — | US | disclosed |
| US-20170158706-A1 | THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166558-A1 | O-GLCNAC TRANSFERASE (OGT) INHIBITORS AND USES THEREOF | OGA, OGT, CSGALNACT1 | HCAR2 3949/4885PDE3B 4075/4885PDE3A 4419/4885 |
| US-10183950-B2 | Thienopyrimidine inhibitors of atypical protein kinase C | PRKCQ, PRKDC, PRKACA | HCAR2 4640/4885PDE3B 1746/4885PDE3A 2148/4885 |
| US-20190106433-A1 | THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | PRKX, PRKCQ, PRKACA | HCAR2 4503/4885PDE3B 1084/4885PDE3A 1261/4885 |
| US-10954251-B2 | Thienopyrimidine inhibitors of atypical protein kinase C | PRKX, PRKCQ, PRKACA | HCAR2 4503/4885PDE3B 1084/4885PDE3A 1261/4885 |
| US-20170158706-A1 | THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | PRKCQ, PRKDC, PRKACA | HCAR2 4640/4885PDE3B 1746/4885PDE3A 2148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.